The ACTC1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the 143B human osteosarcoma cell line, featuring targeted disruption of the ACTC1 locus. This polyclonal pool retains genetic heterogeneity while achieving loss of gene function, enabling robust and unbiased functional analyses in a cell population context.
The 143B cell line is a well-characterized, thymidine kinase-deficient (TK-) human osteosarcoma model with high metastatic potential. Derived from the HOS cell line, 143B is extensively utilized to study tumor cell migration, invasion, and metastasis. Its TK- status facilitates selection in HAT medium, and its well-documented signaling networks and adherent growth make it an ideal host for CRISPR-based gene editing and downstream phenotypic assays.
ACTC1 encodes cardiac alpha-actin, a major constituent of the sarcomeric thin filament required for cardiac muscle contraction. Transcription is regulated by the cardiac transcription factors SRF, MEF2, GATA4, and TBX5. The protein assembles into F-actin and directly interacts with tropomyosin, the troponin complex (troponin T, I, C), myosin heavy chain, alpha-actinin, and nebulin to orchestrate sarcomere organization. This network includes pathway components ACTC1, MYH6, TNNT2, TPM1, and TTN. Beyond its sarcomeric role, ACTC1 modulates actin cytoskeleton signaling, affecting cell shape, adhesion, and motility.
In the 143B metastatic osteosarcoma background, ACTC1 knockout establishes a unique system for exploring non-canonical functions of cardiac actin in a mesenchymal cancer context. The model enables dissection of how sarcomeric actin isoforms influence actin cytoskeleton dynamics, cell adhesion, and migration??processes central to cancer cell dissemination. It also offers a simplified cellular platform to study the pathological consequences of ACTC1 dysregulation observed in dilated cardiomyopathy, hypertrophic cardiomyopathy, atrial septal defects, and congenital heart defects.
This polyclonal knockout cell product is suitable for a wide array of applications. Researchers can assess protein expression via western blotting, visualize F-actin structures with phalloidin staining or immunocytochemistry, and measure cell migration and invasion with wound healing and transwell assays, as well as proliferation rates. The cells are valuable for drug screening campaigns targeting actin-mediated pathways relevant to both cardiomyopathies and cancer metastasis. For further inquiries, please contact Ascent Research.
